Global prophylaxis trends in hemophilia: a macroeconomic analysis and its association with world development indicators.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2024-11-18 DOI:10.1080/17474086.2024.2429606

M Joseph John, Jeff Stonebraker, Aikaj Jindal, Ellia Tootoonchian, Glenn P Pierce, Emna Gouider, Arihant Jain, Donna Coffin

{"title":"Global prophylaxis trends in hemophilia: a macroeconomic analysis and its association with world development indicators.","authors":"M Joseph John, Jeff Stonebraker, Aikaj Jindal, Ellia Tootoonchian, Glenn P Pierce, Emna Gouider, Arihant Jain, Donna Coffin","doi":"10.1080/17474086.2024.2429606","DOIUrl":null,"url":null,"abstract":"Introduction: Prophylaxis is the recommended management strategy for all persons with hemophilia (PwH), yet its adoption is uneven worldwide.Areas covered: This analysis examines global disparities in hemophilia care, focusing on global prophylactic coverage and its correlation with the World Bank's world development indicators. It outlines the disproportionate consumption of clotting factors and non-factor concentrates in high-income countries compared to lower-income counterparts and the challenges of expanding prophylaxis coverage in under-resourced settings. The analysis integrates socioeconomic data with global health indicators to understand these disparities and advocates for increased distribution of treatment resources across all income levels, emphasizing the need for policy changes to improve hemophilia care worldwide. Studies addressing the prophylaxis perspectives in hemophilia were selected using PubMed and Google Scholar platforms (unlimited time frame). Articles were supplemented with WFH's annual surveys and guidelines, including the WFH Global Survey 2022, WFH Guidelines for the Management of Hemophilia 2020 and World Bank data.Expert opinion: Significant disparities in hemophilia care and factor usage exist between high-income and lower-income countries. Standardized, harmonized metrics for different types of factor consumption are critical to accurately assess and compare hemophilia care on an international basis.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-10"},"PeriodicalIF":2.3000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2024.2429606","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Prophylaxis is the recommended management strategy for all persons with hemophilia (PwH), yet its adoption is uneven worldwide.

Areas covered: This analysis examines global disparities in hemophilia care, focusing on global prophylactic coverage and its correlation with the World Bank's world development indicators. It outlines the disproportionate consumption of clotting factors and non-factor concentrates in high-income countries compared to lower-income counterparts and the challenges of expanding prophylaxis coverage in under-resourced settings. The analysis integrates socioeconomic data with global health indicators to understand these disparities and advocates for increased distribution of treatment resources across all income levels, emphasizing the need for policy changes to improve hemophilia care worldwide. Studies addressing the prophylaxis perspectives in hemophilia were selected using PubMed and Google Scholar platforms (unlimited time frame). Articles were supplemented with WFH's annual surveys and guidelines, including the WFH Global Survey 2022, WFH Guidelines for the Management of Hemophilia 2020 and World Bank data.

Expert opinion: Significant disparities in hemophilia care and factor usage exist between high-income and lower-income countries. Standardized, harmonized metrics for different types of factor consumption are critical to accurately assess and compare hemophilia care on an international basis.

查看原文本刊更多论文

全球血友病预防趋势：宏观经济分析及其与世界发展指标的关联。

导言：预防是针对所有血友病患者（PwH）的推荐管理策略，但在全球范围内，预防的采用率却参差不齐：本分析报告探讨了全球血友病治疗的差异，重点关注全球预防性治疗的覆盖率及其与世界银行世界发展指标的相关性。它概述了高收入国家与低收入国家相比，凝血因子和非因子浓缩物的消耗量不成比例，以及在资源不足的环境中扩大预防性治疗覆盖面所面临的挑战。该分析将社会经济数据与全球健康指标相结合，以了解这些差异，并倡导在所有收入水平上增加治疗资源的分配，强调需要改变政策以改善全球的血友病护理。我们使用 PubMed 和谷歌学术平台（无时间限制）筛选了有关血友病预防观点的研究。文章还辅以世界血友病联合会的年度调查和指南，包括《世界血友病联合会2022年全球调查》、《世界血友病联合会2020年血友病管理指南》和世界银行的数据：高收入国家和低收入国家在血友病治疗和因子使用方面存在巨大差距。针对不同类型的因子消耗量制定标准化的统一指标，对于在国际基础上准确评估和比较血友病护理至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.